Zenlabs Ethica Limited markets and distributes pharmaceutical products in India. It markets analgesics and anti-inflammatory drugs; skin preparations; drugs for neurological and GIT disorders; ear, eye, and nasal drops; anti-diabetic, anti-depressant, anti-infective, anti-emetic, anti-hypertensive, anti-allergic, and anti-cold and cough syrups; steroids and anabolic steroids; nutraceuticals; antacids, enzymes, and appetite stimulants; ayurvedic preparations; soaps; dusting powders; soaps; and other pharmaceutical drugs. The company is also involved in the private label manufacturing of various pharmaceutical products, such as tablets, capsules, injections, syrups, and ointments; and therapeutics, such as anti-infective, anti-obesity, anti-bacterial, anti-hypertensives, anti-fungal, pain killers, and nutritional supplements. It serves customers through a network of distributors and stockists in Myanmar, Indonesia, Malaysia, Thailand, Cambodia, Vietnam, Laos, the Philippines, Singapore, Brunei, Timor-Leste, Bangladesh, and internationally. The company was formerly known as Neelkanth Technologies Limited and changed its name to Zenlabs Ethica Limited in January 2016. The company was incorporated in 1993 and is based in Chandigarh, India.
Metrics to compare | ZNLA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZNLAPeersSector | |
---|---|---|---|---|
P/E Ratio | 68.2x | 18.5x | −0.6x | |
PEG Ratio | 0.63 | 0.32 | 0.00 | |
Price/Book | 2.7x | 3.0x | 2.6x | |
Price / LTM Sales | 0.5x | 3.8x | 3.2x | |
Upside (Analyst Target) | - | −1.1% | 48.4% | |
Fair Value Upside | Unlock | 2.2% | 6.8% | Unlock |